CAR-T prima terapia genica anticancro spiegata dal Prof. Armando Santoro

CAR-T gene therapy is an innovative cellular immunological treatment based on the genetic modification of a patient's T cells. These cells are engineered by inserting a portion of DNA proteins into them, allowing them to recognize and destroy tumor cells. These modified T cells remain circulating in the patient's blood for an extended period of time, allowing for repeated therapeutic action against any remaining tumor cells. The process of preparing the cells is complex and requires a multidisciplinary team, starting with a collection of cells from the patient and sending them to laboratories for genetic modification. This process takes 30 to 40 days, but developments are underway to speed up the process. Centers performing this treatment must be accredited and undergo a process for recognition by the relevant authorities. CAR-T gene therapy is primarily used to treat blood disorders, but developments are also underway to use it in other types of cancer. The first anticancer gene therapy explained by Prof. Armando Santoro, Director of the Humanitas Cancer Center in Milan. How it works, which patients it is aimed at, in which centers it is available and how onco-hematology networks allow speeding up the times of access to therapies and the sharing of data between distant centers, an example: WelCare, the first telemedicine platform specific for CAR-T patients. #CAR-T #genictherapy #oncohematology English: CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a type of innovative immunological cellular therapy for cancer treatment. It involves genetically modifying the patient's T-cells (a type of white blood cell) by inserting a part of DNA proteins into the cells. This way, the modified T-cells can recognize and destroy cancer cells when reintroduced into the patient's bloodstream. The preparation process for CAR-T therapy is complex and requires a multidisciplinary team. It starts with a blood sample from the patient, which is then sent to a laboratory where the T-cells are modified and engineered. The whole process takes about 30 to 40 days. The modified T-cells remain in the patient's blood for a long time, providing a prolonged therapeutic effect. The current CAR-T therapy preparation process takes about 30 to 40 days, but faster methods are being developed and might become the norm in the future. ********************* 🔥 Follow us! Magazine: http://www.PianetaSalute.online IG:   / pianetasalute2.0   Twitter:   / pianetasalute   Facebook:   / pianetasalute   And subscribe to our YouTube channel! 00:00 - Introduction to Cancer Gene Therapy 00:40 - Fundamentals of CAR-T Therapy and Cell Engineering 01:23 - Persistence of Engineered Cells and Therapeutic Action 02:01 - Process of Preparing Cells for CAR-T Therapy 03:19 - Possible Developments to Accelerate Cell Preparation 03:58 - Requirements and Accreditations of CAR-T Therapy Centers 05:15 - Current Indications for CAR-T Treatment 07:06 - Estimated Number of Patient Candidates and Challenges in Accessing Therapy 07:44 - Reasons for the Lack of Therapy 08:27 - Importance of Curative Therapy 09:07 - Toxicity of Quartì Treatment 10:18 - Management of Adverse Conditions 11:30 - Impact of the Health Emergency on Hematology-Oncology 12:46 - Development of the Telemedicine 1:32 PM - The Crucial Role of Empathy in Medicine 2:52 PM - Networking in Hematology-Oncology Using IT Platforms